ClinicalTrials.gg
RecruitingNCT05433142Updated Aug 3, 2026

Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

A Phase 1 interventional study of XmAb819 in Clear Cell Renal Cell Carcinoma, sponsored by Xencor, Inc.. Recruiting at 26 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-03.

Sponsored by Xencor, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2022; still recruiting 4 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
307
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 1,143 studies in Carcinoma, Renal Cell with a site in United States — 155 open to participants now, 279 under way, 26 of them phase 3. Carcinoma, Renal Cell · United States.

Planned enrollment
104th of 1,009
307 · median 40
Started
2022
with 50 others
Phase 1
342 of 1,143
38 open now
Primary completion
2027-02
later than 103 of 277 live
Registered
957th of 1,143
by date

Among the 1,143 studies in Carcinoma, Renal Cell with a site in United States, this one is the 104th largest by planned enrollment of the 1,009 interventional ones that give a count, is one of 51 that started in 2022, is one of 342 in phase 1, reaches primary completion later than 103 of the 277 other live ones, and was the 957th registered.

Carcinoma, Renal Cell

2,041 studies on the registry are indexed under Carcinoma, Renal Cell; 397 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

155 of the 1,143 studies in Carcinoma, Renal Cell with a site in United States are open now. Recruiting first, the newest first:

150 more — sign in →

All 155 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 309 Carcinoma, Renal Cell studies recruiting now, 256 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,143 studies in Carcinoma, Renal Cell with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety and tolerability of XmAb®819 administered intravenous (IV) or subcutaneous (SC) in subjects with relapsed or refractory clear cell renal cell carcinoma and to identify the minimum safe and biologically active dose and the recommended dose (RD).

Read the detailed description

This is a Phase 1, multicenter, open-label, multiple-dose study designed in 2 parts: dose escalation, and dose expansion. The study is designed to establish the dosing schedule of XmAb819 administered IV and the dosing schedule of XmAb819 administered SC. The study is designed to evaluate safety and tolerability; to assess PK/PD and immunogenicity; and to preliminarily assess antitumor activity of XmAb819 in subjects with ccRCC and other solid tumors. All eligible subjects will have relapsed or refractory disease after standard therapy.

03

Conditions studied

  • Clear Cell Renal Cell Carcinoma

Keywords

  • Clear cell Papillary
  • RCC
  • Renal Cell Cancer
  • Kidney Cancer
  • Lung Cancer
  • Colon Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must have by (RECIST 1.1) as assessed by the local site investigator. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.
  • Subjects who have ccRCC, pRCC, NSCLC, and CRC with evidence of disease progression on standard-of-care therapies
  • performance status of 0 or 1.
  • All subjects must have adequate tumor sample available (slides or archival FFPE blocks)

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with an anti-ENPP3/CD203c therapy
  • History of serious allergic or anaphylactic/ reaction to monoclonal antibody therapy
  • Systemic antineoplastic therapy within 5 half-lives on the first dose of study treatment.
  • Failure to recover from any toxicity related to previous anticancer treatment
  • Have known active central nervous system and/or carcinomatous meningitis. Subjects with previously treated may participate provided they are radiologically stable,
  • Active known disease (except that subjects are permitted to enroll if they have vitiligo; type 1 diabetes mellitus; residual hypothyroidism due to an autoimmune condition that is treatable with hormone replacement therapy only; psoriasis, atopic dermatitis, or another autoimmune skin condition that is managed without systemic therapy; or arthritis that is managed without systemic therapy beyond oral acetaminophen and nonsteroidal anti-inflammatory drugs)
  • Evidence of any serious infection requiring IV anti-infective treatment within 14 days prior to the first dose of study drug
  • Have a known additional that is progressing or has required active treatment within the past 2 years
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
307 participants (estimated)

Study arms

  • Experimental
    Dose Escalation and Expansion

    Dose Escalation will establish the dosing schedule for XmAb819 administered IV and the dosing schedule of XmAb819 administered SC. The dosing schedule includes the priming dose, step-up priming dose(s), the minimum safe and biologically active dose. Dose Expansion may administer XmAb819 IV, and XmAb819 SC.

    Biological: XmAb819

Interventions

  • BiologicalXmAb819

    Monoclonal Bispecific Antibody

06

What researchers measure

Primary outcomes

  1. Incidence of treatment-emergent adverse events (safety and tolerability of XmAb819)

    Safety and tolerability as assessed by incidence of TEAEs; incidence of clinically significant changes in safety laboratory tests, PE findings, vital signs, and ECGs; incidence and severity of CRS

    Time frame: 28 days

  2. Incidence of dose limiting toxicities (DLTs)

    Safety and tolerability as assessed by incidence of DLTs and all available data which will be used to determine the optimal dose regimen.

    Time frame: 28 days

Secondary outcomes

  1. Measurement of Cmax

    Peak plasma concentration (Cmax)

    Time frame: 56 days

  2. Measurement of AUCtau

    Area under the plasma concentration versus time curve (AUCtau)

    Time frame: 56 days

  3. Objective Response rate

    Objective response rate (RECIST 1.1 assessment of CT/MRI imaging)

    Time frame: 42 days

  4. Progression-free survival

    Progression-free survival (RECIST 1.1 assessment of CT/MRI imaging)

    Time frame: 42 days

  5. Duration of response

    Duration of response (RECIST 1.1 assessment of CT/MRI imaging)

    Time frame: 42 days

07

Study locations

26 of 26 sites recruiting
  • Xencor Investigative Site
    Phoenix, Arizona 85054, United States
    Recruiting
  • Xencor Investigative Site
    Duarte, California 91010, United States
    Recruiting
  • Xencor Investigative Site
    Sacramento, California 95817, United States
    Recruiting
  • Xencor Investigative Site
    New Haven, Connecticut 06520, United States
    Recruiting
  • Xencor Investigative Site
    Jacksonville, Florida 32224, United States
    Recruiting
  • Xencor Investigative Site
    Atlanta, Georgia 30322, United States
    Recruiting
  • Xencor Investigative Site
    Chicago, Illinois 60611, United States
    Recruiting
  • Xencor Investigative Site
    Chicago, Illinois 60637, United States
    Recruiting
  • Xencor Investigative Site
    Louisville, Kentucky 40207, United States
    Recruiting
  • Xencor Investigative Site
    Rochester, Minnesota 55905, United States
    Recruiting
  • Xencor Investigative Site
    New Brunswick, New Jersey 088901, United States
    Recruiting
  • Xencor Investigative Site
    New York, New York 10032, United States
    Recruiting
  • Xencor Investigative Site
    New York, New York 10065, United States
    Recruiting
  • Xencor Investigative Site
    Charlotte, North Carolina 28777, United States
    Recruiting
  • Xencor Investigative Site
    Durham, North Carolina 27710, United States
    Recruiting
  • Xencor Investigative Site
    Cincinnati, Ohio 45267, United States
    Recruiting
  • Xencor Investigative Site
    Columbus, Ohio 43210, United States
    Recruiting
  • Xencor Investigative Site
    Oklahoma City, Oklahoma 73104, United States
    Recruiting
  • Xencor Investigative Site
    Nashville, Tennessee 37203, United States
    Recruiting
  • Xencor Investigative Site
    Seattle, Washington 98109, United States
    Recruiting
  • Xencor Investigative Site
    Leuven, 3000, Belgium
    Recruiting
  • Xencor Investigative Site
    Bourdeaux, 33075, France
    Recruiting
  • Xencor Investigative Site
    Villejuif, 94805, France
    Recruiting
  • Xencor Investigative Site
    Barcelona, 08035, Spain
    Recruiting
  • Xencor Investigative Site
    Madrid, 28050, Spain
    Recruiting
  • Xencor Investigative Site
    Cambridge, Cambridgeshire CB2 0QQ, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2022 (actual). Primary completion is estimated for Feb 2027, 56 months after the start.

Of 138 industry-sponsored phase 1 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 63. This study's planned 56 months is above that.

Counting every sponsor, half of 220 studies reached it within 50 months; a quarter within 32 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2022
First posted
Jun 27, 2022
StartActual
Jun 13, 2022
Primary completionEst.
Feb 2027
CompletionEst.
Dec 2028
Last update
Aug 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05433142
Lead sponsor
Xencor, Inc.
Responsible party
Sponsor
First posted
Jun 27, 2022
Start date
Jun 13, 2022
Primary completion
Feb 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
Aug 3, 2026

Study contacts

819-01 Study Information
Contact
819-01info@xencor.com
819-01 Study Information
study director · Xencor, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion